Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Rheumatology

Treatment Strategy and Medications for TRAPS

At a Glance

For TRAPS, frequent or severe flares are commonly managed with IL-1 inhibitors such as canakinumab or anakinra to control inflammation between attacks as well as during flares. Mild or rare flares may use on-demand medicines, while SAA and urine testing help monitor organ protection.

Treatment for Tumor Necrosis Factor Receptor 1 Associated Periodic Syndrome (TRAPS) has evolved significantly. The primary goal of modern treatment is no longer just “getting through a flare.” Instead, international guidelines, such as the 2021 EULAR/ACR Points to Consider for IL-1-mediated diseases and the 2015 SHARE recommendations, focus on achieving sustained clinical and laboratory control [1][2].

This means the aim is to quiet the inflammatory pathways entirely—both during active flares and the “intercritical” periods between them—to reduce the risk of long-term damage like kidney failure [3][4]. However, treatment choices are highly individualized; they depend on your attack burden, specific genetic variant, and age.

The Standard of Care: IL-1 Inhibitors

Because TRAPS involves a “short-circuit” in the body’s inflammatory signals, preferred strategies for patients with frequent or severe symptoms are those that block a specific messenger molecule called Interleukin-1 (IL-1) [5][6]. Guidelines now prefer these “IL-1 inhibitors” as the first-line biologic strategy for such patients [2][7].

  • Canakinumab: This is a long-acting biologic typically given as an injection starting every 4 weeks, with longer intervals sometimes tailored by a specialist [8]. In major clinical trials (such as the CLUSTER trial), roughly 73% of TRAPS patients achieved a complete response (based on the trial’s specific endpoint) when the dose was optimized [8]. It is highly effective at keeping inflammation markers like C-reactive protein (CRP) and serum amyloid A (SAA) at healthy levels [2][9].
  • Anakinra: This is a shorter-acting version given as a daily subcutaneous injection [10]. Because it leaves the system quickly, it is sometimes used to see how a patient responds to IL-1 blockade before moving to a longer-acting drug (and its approval for TRAPS varies by country). It has been shown to induce rapid and stable remission, though it frequently causes minor reactions at the injection site [5][6].

Important Biologic Safety Guidance: Biologics suppress parts of your immune system, increasing your risk for serious infections. Before starting, you will undergo infection screening. While on treatment, you should avoid live vaccines, contact your doctor immediately if you develop a fever or infection symptoms, and discuss any planned surgeries [8]. Never stop or change your dose without your clinician’s advice.

The Warning on TNF Inhibitors

You might expect a disease named after the “Tumor Necrosis Factor” receptor to be treated with TNF-blocking drugs (like those used for rheumatoid arthritis). However, in TRAPS, this can be complicated and even risky.

  • Etanercept: This specific TNF inhibitor is sometimes used and has shown some benefit in milder cases, but it is generally considered less effective than IL-1 blockers [11][6].
  • A Critical Warning: Monoclonal antibody TNF inhibitors, such as infliximab and adalimumab, are generally avoided in TRAPS. There are documented cases where these drugs have caused paradoxical inflammation—actually triggering a severe flare or worsening the disease rather than helping it [12][13]. Most specialists strongly advise against their use for TRAPS [12].

On-Demand vs. Maintenance Therapy

For patients with very rare or mild flares (often those with “low-penetrance” variants like R92Q), doctors may start with “on-demand” treatment:

  • NSAIDs and Corticosteroids: Medications like ibuprofen or prednisone can help reduce the intensity of an active flare [14][15]. However, NSAIDs carry risks of gastrointestinal bleeding and kidney injury, and are unsuitable if you are pregnant or have existing kidney issues. Repeated or prolonged corticosteroids have important infection, bone, metabolic, and adrenal risks.
  • The Limitation: While these drugs make you feel better temporarily, they do not consistently prevent the “hidden” inflammation that occurs between flares [16]. If you find yourself needing steroids frequently, or if your labs show high inflammation even when you feel okay, your doctor will likely recommend moving to a maintenance biologic like canakinumab to protect your organs long-term [16][17].

Monitoring for Success

Treatment success is measured not just by how you feel, but by your blood work. Your care team will regularly monitor your serum amyloid A (SAA) and perform urinalysis to check for protein [4][17]. Keeping these markers low is the best way to ensure that the “alarm” in your cells has truly been silenced [2][18].

Common questions in this guide

What medicines are usually used for TRAPS?
For frequent or severe TRAPS flares, IL-1 inhibitors are the preferred biologic treatment. Canakinumab and anakinra can reduce inflammation during attacks and between them, but the choice depends on your flare pattern, genetic variant, age, and local approval.
How are canakinumab and anakinra different for TRAPS?
Canakinumab is a longer-acting injection that is often started every four weeks, while anakinra is a short-acting injection usually given daily. Your specialist may consider how often you flare, how you respond, injection preferences, and whether a short trial of IL-1 treatment is useful.
Should people with TRAPS take TNF inhibitors?
Etanercept may help some people with milder TRAPS but is generally less effective than IL-1 inhibitors. Monoclonal antibody TNF inhibitors such as infliximab and adalimumab are generally avoided because they have been reported to trigger paradoxical inflammation or worsen flares.
When is on-demand treatment enough for TRAPS?
On-demand NSAIDs or corticosteroids may be considered when flares are rare or mild. Because these medicines may not control inflammation between attacks, frequent steroid use or persistently high inflammation markers may lead to maintenance biologic treatment.
How is TRAPS treatment monitored?
Clinicians commonly follow serum amyloid A and other inflammation blood tests, along with urine testing for protein and kidney function. The goal is to keep inflammation low even between flares and reduce the risk of long-term kidney damage.
What should I know before starting a biologic for TRAPS?
Biologic medicines can increase the risk of serious infections, so infection screening is usually done before treatment. Avoid live vaccines while taking them, report fever or infection symptoms promptly, discuss planned surgery, and do not change or stop the dose without your clinician.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my flare frequency and current lab results, do I meet the criteria for starting a maintenance biologic like an IL-1 inhibitor?
  2. 2.Which IL-1 inhibitor do you recommend for me—the daily injection (anakinra) or the monthly injection (canakinumab)—and why?
  3. 3.If I have previously taken or am currently taking a TNF inhibitor like infliximab or adalimumab, should we reconsider this given the risk of paradoxical inflammation in TRAPS?
  4. 4.What is my specific plan for monitoring serum amyloid A (SAA) levels and kidney function to ensure my intercritical inflammation is fully controlled?
  5. 5.If I am still having flares on a standard dose of my biologic, can we discuss adjusting the dose or interval under your supervision?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Recommendations for the management of autoinflammatory diseases.

    ter Haar NM, Oswald M, Jeyaratnam J, et al.

    Annals of the rheumatic diseases 2015; (74(9)):1636-44 doi:10.1136/annrheumdis-2015-207546.

    PMID: 26109736
  2. 2

    The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist.

    Romano M, Arici ZS, Piskin D, et al.

    Annals of the rheumatic diseases 2022; (81(7)):907-921 doi:10.1136/annrheumdis-2021-221801.

    PMID: 35623638
  3. 3

    Real-Life Indications of Interleukin-1 Blocking Agents in Hereditary Recurrent Fevers: Data From the JIRcohort and a Literature Review.

    Vinit C, Georgin-Lavialle S, Theodoropoulou A, et al.

    Frontiers in immunology 2021; (12()):744780 doi:10.3389/fimmu.2021.744780.

    PMID: 34858402
  4. 4

    Recurrent fever and arthralgia as the presentation of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Chinese girl: a case report and review of the literature.

    Chen Y, Huang X, Zheng S, et al.

    Clinical rheumatology 2018; (37(5)):1433-1438 doi:10.1007/s10067-018-4023-4.

    PMID: 29450850
  5. 5

    International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome.

    Ozen S, Kuemmerle-Deschner JB, Cimaz R, et al.

    Arthritis care & research 2017; (69(4)):578-586 doi:10.1002/acr.23120.

    PMID: 27723279
  6. 6

    Systematic literature review of efficacy/effectiveness and safety of current therapies for the treatment of cryopyrin-associated periodic syndrome, hyperimmunoglobulin D syndrome and tumour necrosis factor receptor-associated periodic syndrome.

    Kuemmerle-Deschner JB, Gautam R, George AT, et al.

    RMD open 2020; (6(2)) doi:10.1136/rmdopen-2020-001227.

    PMID: 32723831
  7. 7

    INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry.

    Papa R, Lane T, Minden K, et al.

    The journal of allergy and clinical immunology. In practice 2021; (9(2)):783-791.e4 doi:10.1016/j.jaip.2020.10.053.

    PMID: 33181346
  8. 8

    Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.

    De Benedetti F, Gattorno M, Anton J, et al.

    The New England journal of medicine 2018; (378(20)):1908-1919 doi:10.1056/NEJMoa1706314.

    PMID: 29768139
  9. 9

    Long-Term Efficacy and Safety of Canakinumab in Patients With Tumor Necrosis Factor Receptor-Associated Periodic Syndrome: Results From a Phase III Trial.

    Gattorno M, Obici L, Penadés IC, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2024; (76(2)):304-312 doi:10.1002/art.42695.

    PMID: 37668289
  10. 10

    Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS).

    La Torre F, Muratore M, Vitale A, et al.

    Rheumatology international 2015; (35(11)):1943-7 doi:10.1007/s00296-015-3305-2.

    PMID: 26048626
  11. 11

    Effectiveness of "tumor necrosis factor inhibitors" in monogenic hereditary recurrent fevers in children and adolescents: a systematic review.

    Dhahri R, Boussaid S, Ammar LB, et al.

    Frontiers in immunology 2025; (16()):1710180 doi:10.3389/fimmu.2025.1710180.

    PMID: 41333465
  12. 12

    Novel mutation identified in severe early-onset tumor necrosis factor receptor-associated periodic syndrome: a case report.

    Radhakrishna SM, Grimm A, Broderick L

    BMC pediatrics 2017; (17(1)):108 doi:10.1186/s12887-017-0856-2.

    PMID: 28427379
  13. 13

    Vision-threatening bilateral panuveitis and TRAPS in a child: an uncommon association.

    Cocho L, Urbaneja E, Herreras JM

    International ophthalmology 2019; (39(1)):219-223 doi:10.1007/s10792-017-0785-y.

    PMID: 29256170
  14. 14

    Phenotypic variability in two patients with tumor necrosis factor receptor associated periodic fever syndrome emphasizes a rare manifestation: Immunoglobulin A nephropathy.

    Balci S, Kisla Ekinci RM, Melek E, et al.

    European journal of medical genetics 2020; (63(4)):103780 doi:10.1016/j.ejmg.2019.103780.

    PMID: 31586650
  15. 15

    Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-α Receptor-Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network.

    Gaggiano C, Vitale A, Obici L, et al.

    Mediators of inflammation 2020; (2020()):8562485 doi:10.1155/2020/8562485.

    PMID: 32831641
  16. 16

    The use of JAK inhibitors and tocilizumab in the management of TRAPS: a sibling case study.

    Thai D, Tiller G, Akikusa J, et al.

    Pediatric rheumatology online journal 2026; (24(1)).

    PMID: 42310657
  17. 17

    Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network.

    Vitale A, Obici L, Cattalini M, et al.

    Frontiers in medicine 2021; (8()):668173 doi:10.3389/fmed.2021.668173.

    PMID: 34307404
  18. 18

    Use of the Auto-inflammatory Disease Activity Index to monitor disease activity in patients with colchicine-resistant Familial Mediterranean Fever, Mevalonate Kinase Deficiency, and TRAPS treated with canakinumab.

    Koné-Paut I, Piram M, Benseler S, et al.

    Joint bone spine 2022; (89(6)):105448 doi:10.1016/j.jbspin.2022.105448.

    PMID: 35944600

This page is for informational purposes only and does not constitute medical advice. Your rheumatologist or other clinician can help choose and monitor TRAPS treatment, including biologic medicines.

Get notified when new evidence is published on Tumor necrosis factor receptor 1 associated periodic syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.